Verona Pharma plc (VRP.L) (VRP) Share Price, News & Analysis

ETF Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: 55 to 55
• 52-Week Range: N/A
• Volume: 70,791 shs
• Average Volume: 150,610 shs
• Market Capitalization: £228 million
• Assets Under Management: N/A
• Dividend Yield: N/A
• Net Expense Ratio: 0.00%
• Aggregate Rating: N/A

VRP ETF - Frequently Asked Questions

How were Verona Pharma plc (VRP.L)'s earnings last quarter?

Verona Pharma plc (VRP.L) (LON:VRP) posted its earnings results on Thursday, February, 27th. The company reported ($30.30) earnings per share for the quarter, beating analysts' consensus estimates of ($30.80) by $0.50.

How do I buy shares of Verona Pharma plc (VRP.L)?

Shares of VRP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Verona Pharma plc (VRP.L) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma plc (VRP.L) investors own include Verona Pharma (VRNA), Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL) and Amicus Therapeutics (FOLD).